Calidi Biotherapeutics Reports First Quarter 2024 Operating and Financial Results [Yahoo! Finance]
Calidi Biotherapeutics, Inc. (CLDI)
Company Research
Source: Yahoo! Finance
Presented new data on the mechanisms of action of Calidi's novel immunotherapies at the AACR Annual Meeting Unveiled RTNova systemic platform allowing for ease of administration and ability to target multiple tumor types Completed $6.1 million public offering SAN DIEGO, May 14, 2024 BUSINESS WIRE )--Calidi Biotherapeutics Inc. (NYSE American: CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted virotherapies, today reported its first quarter 2024 operating and financial results and reviewed recent business highlights. "Calidi's current focus is on raising additional capital and implementing continued cost cutting measures in order to advance our promising pipeline of novel immunotherapies designed to successfully target and eliminate solid tumors across the body. We plan to present three posters at ASCO including an update from our ongoing trial with City of Hope for recurrent high-grade glioma," said Allan Camaisa, CEO and Chairman
Show less
Read more
Impact Snapshot
Event Time:
CLDI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLDI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLDI alerts
High impacting Calidi Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CLDI
News
- Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results [Yahoo! Finance]Yahoo! Finance
- Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial ResultsGlobeNewswire
- Calidi Biotherapeutics Announces Launch of Nova Cell Subsidiary and $3 Million Aggregate Investment from Dr. Ronald RigorGlobeNewswire
- Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology PlatformGlobeNewswire
- Calidi Biotherapeutics Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board [Yahoo! Finance]Yahoo! Finance
CLDI
Sec Filings
- 9/24/24 - Form 8-K
- 9/12/24 - Form 8-K
- 9/11/24 - Form SC
- CLDI's page on the SEC website